Osang Healthcare

What Osang Healthcare does

Osang Healthcare (주식회사 오상헬스케어, KOSDAQ: 036220) is a South Korea-based in-vitro diagnostic (IVD) medical device company founded in 1996 and headquartered in Anyang-si, Gyeonggi-do. The company develops, manufactures, and sells diagnostic products across biochemistry, immunology, and molecular diagnostics, with a portfolio spanning blood glucose monitors (GluNEO H/plus/dual/lite, HealthPro, GLUCOLAB Auto-coding), HbA1c analyzers (CLOVER A1c Expert), liver function systems (CLOVERDX L1), and molecular diagnostic kits (GeneFinder COVID-19 RealAmp, GeneFinder HLA-ABDR, GeneFinder HPV Liquid Bead MicroArray). Technical capabilities include FDA 510(k) cleared products, CE and ANVISA certifications, and proprietary assay platforms such as the world's first FDA-cleared simultaneous COVID-19/Influenza A&B antigen self-test (QuickFinder).

The company operates a dual go-to-market model. On the consumer side, Osang sells self-testing diagnostic devices through its corporate website and retail channels targeting individual diabetes patients and health-conscious consumers. On the enterprise side, it serves healthcare companies, laboratories, hospitals, and government health programs through OEM/ODM contract manufacturing and bulk distribution partnerships. Revenue is generated via hardware sales of diagnostic instruments, recurring consumable revenue from reagent strips and test cartridges, and contract manufacturing fees. Over 96% of revenue comes from global markets with distribution across 100+ countries, reducing single-market dependence but requiring sustained international regulatory and channel management.

Osang is publicly listed on KOSDAQ and is pursuing an explicit strategic evolution from a pure-play IVD manufacturer to an integrated Global Healthcare Company, with stated intent to expand into health functional foods, digital healthcare platforms, and data-driven personalized health services. Named anchor customers include the Mexican Government (HbA1c meters for a national diabetes program) and Novo Nordisk (point-of-care HbA1c testing via the Changing Diabetes in Children program). Revenue exhibits a clear COVID-era peak in 2023 followed by normalization, with ongoing product launches across glucose monitoring, HbA1c, infectious disease, and liver function categories indicating continued R&D and pipeline investment.

Name

Osang Healthcare

Legal name

주식회사 오상헬스케어

Website

https://osanghc.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

11–50 employees

Short description

Osang Healthcare (KOSDAQ: 036220) is a South Korea-based in-vitro diagnostic medical device company, founded in 1996, that develops and manufactures blood glucose monitors, HbA1c analyzers, molecular diagnostic kits, and health functional foods. It sells to consumers via retail and to enterprise partners via OEM/ODM manufacturing across more than 100 countries.

Ownership category

akta.pro rank

Product category

In-Vitro Diagnostics (IVD)

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)

akta.pro secondary industries

Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL), Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests) (CRADAMAK), Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK), Home Diagnostic & Self-Test OTC Kits (HLAIADAO)

Keywords

• In-vitro diagnostics
• Blood glucose monitoring
• Point-of-care testing
• Molecular diagnostic kits
• HbA1c analyzers

Headquarters

HQ city

Dongan

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Sale of in-vitro diagnostic medical devices including blood glucose meters, HbA1c analyzers, cholesterol analyzers, and other diagnostic equipment. Revenue generated from both consumer/self-testing products and professional/clinical diagnostic devices.
2. Diagnostic Reagent Strips: Recurring revenue from consumable diagnostic strips and reagents used with their diagnostic instruments for blood glucose monitoring, HbA1c testing, and other biochemical analyses.
3. OEM/ODM Manufacturing: Contract manufacturing partnerships with global healthcare companies for OEM/ODM production of diagnostic devices and solutions.
4. Health Functional Foods: Personalized health functional food solutions based on individual health status and analytical data for chronic disease prevention and health management.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels3 records

Core offering

Osang Healthcare manufactures and sells in-vitro diagnostic (IVD) medical devices across biochemistry, immunology, and molecular diagnostics. Its commercial offering spans branded blood glucose monitors, HbA1c analyzers, liver function analyzers, and molecular diagnostic test kits, supplied both as its own branded products and through OEM/ODM partnerships with global healthcare companies, with consumable test strips and reagents providing recurring revenue.

Product overview

Osang Healthcare is an in-vitro diagnostic (IVD) medical device company that offers a comprehensive portfolio across biochemistry, immunology, and molecular diagnostics. The product lineup includes: blood glucose monitoring devices (GluNEO H, GluNEO plus, GluNEO dual, GluNEO lite, GLUCOLAB Auto-coding, HealthPro), HbA1c analyzers (CLOVER A1c Expert), liver function systems (CLOVERDX L1 Liver System), and molecular diagnostic kits (GeneFinder™ COVID-19 Fast RealAmp Kit, GeneFinder™ HLA-ABDR RealAmp kit, GeneFinder™ HPV Liquid Bead MicroArray Genotype kit). The company also offers health functional foods. Products are exported to over 100 countries worldwide through diverse global partnerships.

Differentiator

Problem solved

Functional benefit

Products and services

• GluNEO H (글루네오 에이치) Blood glucose meter featuring GDH enzyme technology with the widest hematocrit range, large display, and color indicator for easy visual recognition of glucose levels; intended for self-monitoring of blood glucose by individuals with diabetes.
• GluNEO plus Blood glucose monitoring system with advanced features for diabetes management.
• GluNEO dual (글루네오 듀얼) Dual-function blood glucose meter for comprehensive diabetes monitoring.
• GluNEO lite (글루네오 라이트) Compact and lightweight blood glucose meter for easy daily use.
• GLUCOLAB Auto-coding (글루코랩 오토코딩) Blood glucose meter with wide LCD display, compact size, and strip ejector feature for easy and convenient blood glucose monitoring.
• HealthPro (헬스프로) FDA-cleared blood glucose meter with ultra-low blood sample requirement (0.5 µL) and compact design, intended for self-monitoring of blood glucose.
• CLOVER A1c Expert HbA1c analyzer with enhanced usability through cartridge improvements and auto calibration for accurate glycated hemoglobin measurement; intended for clinical and point-of-care use.
• CLOVERDX L1 Liver System (클로버디엑스 엘원 리버 시스템) Liver function diagnostic system for measuring AST and ALT markers from capillary and venous blood samples, with a console/module design and 5-minute measurement time; intended for clinical point-of-care liver function testing.
• QuickFinder™ COVID-19/Flu Antigen Self Test World's first FDA 510(k)-cleared rapid antigen test for simultaneous detection of COVID-19 and Influenza A&B, designed for at-home self-testing by consumers.
• GeneFinder™ COVID-19 Fast RealAmp Kit Real-Time PCR kit for detection of SARS-CoV-2 with N gene, RdRP gene, and E gene targets, validated for use with major PCR platforms; intended for laboratory molecular diagnostics.
• GeneFinder™ HLA-ABDR RealAmp kit RealAmp PCR kit for HLA-A, HLA-B, and HLA-DRB1 tissue typing from whole blood samples, intended for transplant matching and immunogenetics laboratories.
• GeneFinder™ HPV Liquid Bead MicroArray Genotype kit Liquid Beads Microarray (LBMA) kit for genotyping 32 types of Human Papillomavirus (HPV) from cervical swab samples, intended for clinical HPV screening.
• Health Functional Foods Personalized health functional food solutions based on individual health status and analytical data, using scientifically validated functional ingredients to support chronic disease prevention and health management.

Quantifiable outcome

• Over 96% of revenue generated from global markets
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• LifeScan: LifeScan (formerly Johnson & Johnson Diabetes Care, now owned by Platinum Equity) manufactures the OneTouch brand of blood glucose monitoring systems. Established broad incumbent in BGM competing globally with Osang Healthcare, particularly in retail pharmacy channels and consumer self-monitoring.
• Abbott Diabetes Care: Abbott Diabetes Care is the global market leader in blood glucose monitoring (FreeStyle Libre CGM, FreeStyle meters) within Abbott's broader diagnostics portfolio. Indirect competitor defining the high end of the BGM/CGM market against which Osang positions its value-tier products.
• Roche Diagnostics: Roche Diagnostics is the global IVD market leader offering Accu-Chek blood glucose monitors, cobas clinical chemistry platforms, and a broad molecular diagnostics portfolio. Broad incumbent that defines premium IVD pricing and competes with Osang in clinical BGM, HbA1c, and molecular diagnostics.

Direct peers

• SD Biosensor: SD Biosensor is a Korean IVD company specializing in rapid diagnostic test kits for infectious diseases (COVID-19, influenza, HIV) and clinical chemistry products. Direct peer in molecular diagnostics and rapid antigen testing with similar global export footprint and KOSDAQ-listed public profile.
• Sinocare: Sinocare is a Chinese IVD company and one of the largest BGM manufacturers globally (Acon acquired by Sinocare in 2016). Direct peer in affordable blood glucose monitoring devices for emerging markets, with similar value proposition targeting LMIC diabetes screening programs.
• i-SENS: i-SENS is a Korean IVD company and a leading manufacturer of blood glucose monitoring systems (CareSens brand) and electrolyte analyzers. Direct peer to Osang Healthcare in the Korean BGM market, with overlapping presence in global LMIC markets and similar OEM/ODM capabilities in electrochemical biosensors.
• EKF Diagnostics: EKF Diagnostics is a UK-based IVD company specializing in blood glucose monitoring (QuikRead), HbA1c analyzers (QuikLab), and point-of-care diagnostics. Direct peer in POC and clinical chemistry analyzers with similar focus on affordable testing for primary care and emerging market customers.
• ARKRAY: ARKRAY is a Japanese IVD manufacturer specializing in blood glucose monitoring (GLUCOCARD), HbA1c analyzers, and urine chemistry analyzers. Direct competitor to Osang in the clinical BGM and HbA1c analyzer segments with comparable regulatory certifications and global distribution through distributors.
• ACON Laboratories: ACON Laboratories is a US-headquartered (China-manufactured) IVD company specializing in blood glucose monitoring systems, rapid diagnostic tests, and clinical chemistry reagents. Direct competitor to Osang Healthcare across BGM strips, OTC self-tests, and OEM/ODM diagnostic manufacturing with similar global distribution profile.
• TaiDoc Technology: TaiDoc Technology is a Taiwanese IVD manufacturer specializing in blood glucose monitoring systems, HbA1c analyzers, and multi-parameter clinical chemistry devices under the FORA brand. Direct peer in BGM and OEM/ODM manufacturing with comparable global distribution across consumer and clinical channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/HealthcareOsang
• LinkedInlinkedin.com/company/osang-llc

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Osang Healthcare